Market Research Reports, Inc.

MarketResearchReports.com: The Market Value for Monoclonal Antibodies (MAbs) in Colorectal Cancer Treatment Is Expected to Reach $5.5 Billion by 2019

Market Research Reports, Inc. has announced the addition of “Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth” research report to their offering.

 
Repost This

Lewes, DE -- (SBWIRE) -- 12/31/2013 -- The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment will experience a moderate increase from $3.7 billion in 2012 to $5.5 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%.

For more information please visit: http://www.marketresearchreports.com/gbi-research/monoclonal-antibodies-market-colorectal-cancer-2019-favorable-pricing-policy-us-and

The company’s report states that this moderate growth is due to the slow rise of the prevalent population and weakness of the late-stage pipeline. Currently, there is only one mAb product in Phase III development for the treatment of colorectal cancer, named IMC-1121B.

Analyst of this report says: “The efficacy of this drug has not yet been proven in large-scale, placebo-controlled Phase III trials, which creates an element of uncertainty in terms of the outcome of these products. As such, this weak late-stage pipeline is not expected to drive market growth to a significant extent during the forecast period.”

The current metastatic colorectal cancer market is dominated by three mAbs- Avastin, Erbitux and Vectibix - which are far more efficacious than the targeted small molecule therapies also marketed for this setting. Therefore, GBI Research believes there is a strong opportunity for the entry of new mAbs into the market, as long as they prove superior efficacy when compared to Avastin.

Analyst says: “A product that can attain first-line status in the treatment of colorectal cancer, or even second-line status by displacing Erbitux and Vectibix, would have access to a considerable patient population and be able to generate a substantial amount of revenue.

“Furthermore, there are currently no approved mAbs in the early-stage setting for colorectal cancer, reflecting an additional opportunity for the development of new products,” the analyst concludes.

This report provides in-depth analysis of three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. It also gives a comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period.

Browse other market research reports in diseases at http://www.marketresearchreports.com/diseases

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Follow us on Vimeo : http://vimeo.com/marketresearchreports